Stock 1SXP SCHOTT PHARMA AG & CO. KGAA
Add to a list
To use this feature you must be a member
Log inSign up

Other languages SCHOTT Pharma AG & Co. KGaA Deutsche Boerse AG

Equities

1SXP

DE000A3ENQ51

Market Closed - Deutsche Boerse AG
Other stock markets
 11:00:15 2024-05-31 am EDT 		5-day change 1st Jan Change
29.28 EUR +3.24% Intraday chart for SCHOTT Pharma AG & Co. KGaA -4.00% -13.37%
May. 28 SCHOTT PHARMA : Berenberg reiterates its Neutral rating ZD
May. 21 Deutsche Bank Research lowers target for Schott Pharma - 'Buy' DP

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SCHOTT PHARMA : Berenberg reiterates its Neutral rating
SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Deutsche Bank Research senkt Ziel für Schott Pharma - 'Buy'
SCHOTT PHARMA : Receives a Buy rating from Deutsche Bank
UBS senkt Ziel für Schott Pharma auf 33 Euro - 'Neutral'
SCHOTT PHARMA : UBS reiterates its Neutral rating
SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Barclays senkt Schott-Pharma-Ziel auf 25 Euro - 'Equal Weight'
SCHOTT PHARMA : Deutsche Bank reiterates its Buy rating
SCHOTT PHARMA : Barclays remains Neutral
Schott Pharma fallen stark - 'Hohe Abhängigkeit von Endmärkten'
SCHOTT PHARMA : Gets a Neutral rating from UBS
Schott Pharma warnt vor schwachen Verkäufen von Spritzen - Kursrutsch
Schott Pharma fallen stark
SCHOTT PHARMA : Jefferies reiterates its Neutral rating
Schott Pharma warnt vor schwachen Verkäufen von Spritzen im kommenden Jahr
SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes
SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1SXP Stock
  4. 1SXP Stock
  5. News SCHOTT Pharma AG & Co. KGaA
  6. Other languages